Healthdirect Free Australian health advice you can count on.

Medical problem? Call 1800 022 222. If you need urgent medical help, call triple zero immediately

healthdirect Australia is a free service where you can talk to a nurse or doctor who can help you know what to do.

beginning of content

Brand name: Avastin TM

Active ingredients: bevacizumab

What it is used for

Metastatic ColorectaI Cancer AVASTIN (bevacizumab) in combination with fluoropyrimidine-based chemotherapy is indicated for the treatment of patients with metastatic colorectal cancer. Locally recurrent or metastatic Breast Cancer AVASTIN (bevacizumab) in combination with paclitaxel is indicated for the first-line treatment of metastatic breast cancer in patients in whom an anthracycline-based therapy is contraindicated.(see Clinical Trials). Advanced, metastatic or recurrent non-squamous Non-Small Cell Lung Cancer (NSCLC) AVASTIN (bevacizumab), in combination with carboplatin and paclitaxel, is indicated for first-line treatment of patients with unresectable advanced, metastatic or recurrent, non-squamous non-small cell lung cancer. Advanced and/or metastatic RenaI Cell Cancer AVASTIN (bevacizumab) in combination with interferon alfa-2a is indicated for treatment of patients with advanced and/or metastatic renal cell cancer Grade IV Glioma AVASTIN (bevacizumab) as a single agent, is indicated for the treatment of patients with Grade IV glioma after relapse or disease progression after standard therapy, including chemotherapy. EpitheliaI Ovarian, Fallopian Tube or Primary Peritoneal Cancer AVASTIN (bevacizumab) in combination with carboplatin and paclitaxel, is indicated for first-line treatment of patients with advanced (FIGO stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer. Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer AVASTIN (bevacizumab), in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, is indicated for the treatment of patients with first recurrence of platinum-sensitive, epithelial ovarian, fallopian tube, or primary peritoneal cancer who have not received prior bevacizumab or other VEGF-targeted angiogenesis inhibitors. AVASTIN (bevacizumab) in combination with paclitaxel, topotecan or pegylated liposomal doxorubicin is indicated for the treatment of patients with recurrent, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than two prior chemotherapy regimens, and have not received any prior anti-angiogenic therapy including bevacizumab. Cervical Cancer AVASTIN (bevacizumab) in combination with paclitaxel and cisplatin is indicated for the treatment of persistent, recurrent or metastatic carcinoma of the cervix. AVASTIN (bevacizumab) in combination with paclitaxel and topotecan is an acceptable alternative where cisplatin is not tolerated or not indicated.

How to take it

The way to take this medicine is: Intravenous. This medicine or fluids is given through a needle or tube (catheter) inserted into a vein.

  • Store at 2 to 8 degrees Celsius
  • Do not Freeze
  • Refrigerate
  • Protect from Light
  • Shelf lifetime is 2 Years.

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.

Always read the label. If symptoms persist see your healthcare professional.

Visual appearance

Clear to slightly opalescent, colourless to pale brown solution.

Do I need a prescription?

This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.

Pregnant or planning a pregnancy?

For the active ingredient bevacizumab

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

Download leaflet

For side effects, taking other medicines and more

Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website

Reporting side effects

You can help ensure medicines are safe by reporting the side effects you experience.

You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems

Back to top back to top

Need more information?

These trusted information partners have more on this topic.

Top results

Treatments for Renal Cell Cancer (RCC) | HealthEngine Blog

Kidney cancer or renal cell carcinoma can be treated with nephrectomy (surgical kidney removal), chemotherapy and targeted cancer therapy.

Read more on HealthEngine website

Macular degeneration | HealthEngine Blog

Macular degeneration affects the nerves in the macula, the central portion of the eye's retina. It affects high acuity vision needed for sharp focus.

Read more on HealthEngine website

Diabetic macular oedema | HealthEngine Blog

Macular oedema is a diabetic eye disease and a type of diabetic retinopathy cause by changes to the eye's blood vessels. It can cause blindness.

Read more on HealthEngine website

Biological Therapy (Biotherapy) | HealthEngine Blog

Biological therapy, or biotherapy, immunotherapy or biological response modifiers, are gaining increasing prominence as anti-cancer agents. They may be used either alone or in combination with traditional anti-cancer treatments such as chemotherapy.

Read more on HealthEngine website

Diabetic eye disease: Proliferative diabetic retinopathy | HealthEngine Blog

Proliferative diabetic retinopathy is a sight-threatening eye disease characterised by neovascularisation, the abnormal growth of blood vessels, in the eye.

Read more on HealthEngine website

Healthdirect 24hr 7 days a week hotline

24 hour health advice you can count on

1800 022 222

Government Accredited with over 140 information partners

We are a government-funded service, providing quality, approved health information and advice

Australian Government, health department logo ACT Government logo New South Wales government, health department logo Northen Territory Government logo Government of South Australia, health department logo Tasmanian government logo Government of Western Australia, health department logo